Green light for TyraTech to sell Vamousse brand to Alliance Pharma

Life sciences company TyraTech has been given permission by its shareholders to sell its human lice products brand Vamousse to Alliance Pharma for an initial cash consideration of $13m with further payments of up to $4.5m based on the achievement of agreed sales performance targets for Vamousse in 2019 and 2020.

The sale will now proceed with immediate effect.

Following the sale, TyraTech intends to focus on the opportunities within the estimated $6bn addressable animal health market for control of insects and parasites.